TLR1 and hepatocellular carcinoma: We further report on the clinical application of a DNAJB1-PRKACA neoepitope-based personalized peptide vaccine adjuvanted with the TLR1/2 agonist XS1532 and MontanideTM ISA51 VG in a single FL-HCC patient.